Itragerm

Itraconazole, the active ingredient in Itragerm, is an azole antifungal presented as an oral formulation for systemic use. It is employed to treat a range of fungal infections—including dermatophytosis, onychomycosis, blastomycosis, histoplasmosis and other systemic mycoses—in adult patients requiring oral therapy.

GNH USA supplies Itragerm as a licensed, GDP‑compliant product sourced from the European Union, providing hospitals, pharmacies and clinics worldwide with a reliable source of this antifungal medication. The company adheres to international quality standards and offers regulatory support for importation.

Itraconazole is used to treat fungal infections affecting the skin, nails and internal organs.

Dermatophytosis: reduces fungal growth on the skin, alleviating rash and itching. Onychomycosis: eradicates dermatophytes in the nail plate, promoting regrowth of healthy nail. Systemic mycoses: controls disseminated fungal infections such as candidiasis and aspergillosis. Blastomycosis: eliminates Blastomyces dermatitidis, improving pulmonary and extrapulmonary disease. Histoplasmosis: suppresses Histoplasma capsulatum, aiding resolution of respiratory and systemic manifestations.

Itraconazole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild stomach upset often occurring early in therapy. - Headache: transient headache reported by some patients. - Abdominal pain: discomfort or cramps in the stomach area. - Elevated liver enzymes: mild, reversible increase detected in blood tests.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury, jaundice or hepatitis. - Cardiac arrhythmias: QT prolongation leading to irregular heart rhythm. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Itragerm, clinicians should consider several safety measures.

Liver function monitoring: assess baseline and periodic liver enzymes. Drug interactions: review concomitant medications for CYP3A4 substrates. Pregnancy and lactation: avoid use unless benefits outweigh risks. Renal impairment: adjust dose in severe renal dysfunction. Avoid grapefruit: can increase itraconazole levels. Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Itraconazole interacts with several medicines; awareness of interaction severity guides management.

Major Interactions (Avoid): - Rifampin: induces metabolism, markedly reduces itraconazole exposure. - Ketoconazole: additive hepatotoxicity risk. - Certain statins (e.g., simvastatin): increased risk of myopathy.

Moderate Interactions (Monitor Closely): - Calcium channel blockers (e.g., verapamil): may increase itraconazole levels, monitor for toxicity. - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect, monitor INR closely.